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Type A synoviocytes and synovial tissue macrophages express high levels of class
II MHC proteins (also known as la) on their surface in rheumatoid arthritis (RA) ,
(1) . Although the mechanism of Ia induction is not known, IFN-y has been pro-
posed as the major factor responsible forthis observation (2). However, we have re-
cently demonstrated that the rheumatoid joint contains very low levels of IFN--y
that are unlikely to account for the high class II antigen expression (3, 4). In addi-
tion, an Ia-inducing factor was observed in rheumatoid joint samples that was not
neutralized by antibody to IFN-y (3) .
These data suggest that afactor otherthan IFN-y is responsible for the activated
phenotype oftypeA synoviocytesand macrophagesin RA synovium . Inour studies
on the cytokine profile in RA, we have recently demonstrated granulocyte/macro-
phageCSF(GM-CSF) in rheumatoid synovial effusions and in supernatants of cul-
turedRA synovial tissue cells (5). GM-CSF induces surface Ia expression inmurine
macrophages (6-8), but similar activity has not been reported in humans . To ex-
amine the possibility that GM-CSF is responsible forthe high level of surface HLA-
DRon macrophage lineage cells in theRA synovium, we studied the effect ofGM-
CSF and a panel of other cytokines on human monocyte la expression . This cell
typewas selected becauseofitseasy accessibilityandthe fact that tissue macrophages
and typeA synoviocytes are probably derived from bone marrow precursors of the
monocyte lineage (9) . Of the cytokines tested in these experiments, only GM-CSF
and IFN-y were potent Ia induers . Although, the Ia-inducing factor produced by
RA synovial tissue in vitro wasnotneutralized by anti-IFN-y antibodies, it wasblocked
by specific antibody toGM-CSF Becausewe have also recently measured significant
levels ofGM-CSF in rheumatoid joint samples (5), it is likely that this cytokine is
an important Ia-inducing factor in the rheumatoid synovium .
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CYTOKINE-MEDIATED INDUCTION OF HLA-DR, DQ ON MONOCYTES
Materials and Methods
Cell Preparation.
￿
Blood was drawn from healthy volunteers into heparinized syringes and
diluted 1 :1 with PBS. Mononuclear cellswere separated by centrifugation on a discontinuous
Ficoll-Hypaque density gradient at 300 g for 40 min, washed, and resuspended in RPMI
1640 with 10% heat-inactivated FCS (<0.006 ng/ml of endotoxin; Irvine Scientific, Santa
Ana, CA), gentamicin, penicillin, streptomycin, and glutamine. Cells (0.5-1 x 107) were in-
cubated in 35-mm polystyrene petri dishes (Costar, Cambridge, MA) at 37'C and 5% C02
in a humidified incubator for 1.5-2.5 h. After this time, nonadherent cells were washed off
and fresh medium was added to the dishes. Adherent cells were >90% esterase-positive and
<1% C133-positive.
Culture Conditions.
￿
Cells were cultured in the presence of various concentrations of the
different cytokines at 37°C and 5% C02 for 48 h unless otherwise stated. The dishes were
then placed at 4°C for 30 min and gently scraped with a rubber policeman to remove ad-
herent cells. Viability at this time was >95% (trypan blue dye exclusion). Harvested cells
were prepared for staining with mAbs (see below). Cytokine-treated cells were compared
with cells cultivated in medium alone.
Reagents.
￿
Recombinant hGM-CSF (specific activity 108 U/mg, LPS content of the con-
centrated stock <0.025 ng/ml, purity >95%) and hIFN--y (specific activity 2 x 10' IRU/mg,
LPS <0.048 ng/ml, purity >98%) were provided by Amgen Biologicals (Thousand Oaks, CA).
Recombinant hIL-1-ß (specific activity 5 x 108 U/mg, LPS <0.005 ng/ml, purity >95%) was
purchased from the same company. Recombinant hIL-3 (specific activity 108 CFU/mg, LPS
<0.1 ng/ml, purity >95%) was purchased from Genzyme (Cambridge, MA). Recombinant
hIL-4 (specific activity 108 U/mg, LPS <0.5 ng/ml, purity >95%) was obtained from Im-
munex Corp. (Seattle, WA). Recombinant hIL-6 (specific activity 5 x 109 U/mg, LPS <0.006
ng/ml, purity >95%) was a gift from Dr. Martin Lotz (Scripps Clinic Research Foundation,
La Jolla, CA). Recombinant hIL-2 (specific activity 3 x 106 U/mg, LPS <0.012 ng/ml, pu-
rity >95%) was obtained from Cetus Corp. (Emeryville, CA) and hCSFI (specific activity
7 x 10' U/mg, LPS <0.1 ng/ml, purity >95%) was a gift from Dr. R. Halenbeck, Cetus
Corp. Recombinant hTNFa (specific activity 5 x 101 U/mg, LPS <0.008 ng/ml, purity
>95%) was provided by Genentech (South San Francisco, CA). In each case, the final con-
centration of LPS in culture after dilution of recombinant cytokine was <0.005 ng/ml. Poly-
myxin B (7.900 U/mg) was purchased from Sigma Chemical Co. (St. Louis, MO).
Antibodies.
￿
HLA-DR was identifiedwith the mAb 12 (IgG2a, ascites fluidpurified by ion
exchange chromatography; Coulter Immunology, Hialeah, FL). Leu-10 (IgGI, Becton Dick-
inson & Co., Mountain View, CA) was used to detect HLA-DQ. CD14 is a monocyte differen-
tiation antigen detected with Mo2 (IBM, ascites fluid purified by ion exchange chromatog-
raphy; Coulter Immunology) (10). Pooled mouse IgG (Cappel Laboratories, Malvern, PA)
or monoclonal IBM (Bionetics, Kensington, MD) were used as controls for most im-
munofluorescence studies. In some experiments, isotype-matched mouse IgG2a and IgG1
(Coulter Immunology) were used as controls and gave results identical to the pooled IgG.
Immunofluorescence.
￿
Cells were stained with mAbs and secondary reagents (FITC-conjugated
goat anti-mouse IgG/IBM antibody; Tago, Burlingame, CA), as previously described (11).
In some experiments, biotinylated Mo2 and avidin-conjugated FITC (E-Y Laboratories, San
Mateo, CA) were used. The results were measured by flow cytometry (see below).
Synovial Tissue Supernatants.
￿
Supernatants were prepared from enzymatically dispersed sy-
novial tissue specimens obtained from patients with longstanding seropositive RA as previ-
ously described (3). Briefly, the tissue was minced and incubated at 37°C in RPMI 1640
supplemented with 1 mg/ml collagenase (CooperBiomedical, Inc., Malvern, PA) and 50 pg/ml
deoxyribonuclease (Sigma Chemical Co.). The cells were filtered, washed extensively, and
cultured in plastic petri dishes in RPMI 1640 plus 10% FCS at a density of 2-3 x 106/ml
at 37'C in 5% C02. Supernatants were harvested after 72 h, filtered and frozen at -70°C
until used.
These supernatants were tested for classII antigen-inducing activity at a 1 :5 dilution under
the conditions described above. In some experiments the supernatants were incubated for
1 h at room temperature with monoclonal anti-GM-CSF (12) (affinity-purified ascites fluid;ALUARO-GRACIA ET AL.
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kindly provided by Dr. Ken Kaushansky, University of Washington, Seattle, WA) or anti-
IFN--y (Chemicon, El Segundo, CA) antibodies before theiraddition to the monocyte cultures.
Flow Cytometry. FACS was performed on a cytofluorograf Its (Ortho Diagnostics, Rar-
itan, NJ) as previously described (11). 5 x 103 cells in a monocyte-enriched region, as de-
termined by forward and 90° light scatter (containing 90-95% nonspecific esterase-positive
cells and 75-80% Mot' cells) were analyzed from each sample. The fluorescence gain was
adjusted in every experiment so that -5% of cellswere positive in the highest fluorescence
channel ofthe sample with greatest fluorescence intensity. All data were displayed on a linear
scale ofincreasing fluorescence without specific units. The results are presented as absolute
or relative mean fluorescence channel (MFC) oftotal cells, thelatter being obtained by dividing
the absolute MFC ofa sample by that of control cells that had been in culturewithout cytokine
for an identical period oftime. Forward lightscatter was used to estimate the relative cell volume.
Northern BlotAnalysis.
￿
Total cytoplasmic RNA was isolated from adherent peripheral blood
cellsusingthe acid guanidine phenol chloroformmethod (13). 20 gg oftotalRNA was dena-
tured and run on a formaldehyde containing 1.2 % agarose gel and blotted onto a nylonmem-
brane (Schleicher & Schuell, Inc., Keene, NH). The HLA-DR /3 chainprobe was obtained
from Dr. Per Peterson (Scripps Clinic Research Foundation) and the actin probe was a gift
from Dr. Raymond Taetle (San Diego, CA). Probes were radiolabeled with [32p]dCTP
(Amersham Corp., Arlington Heights, IL) by the random primermethod (Bethesda Research
Laboratories, Gaithersburg, MD). The nylon filter was simultaneously hybridized to both
probes overnight at 42°C and washed twice on 2 x SSC and 0.1% SDS followed by one wash
in 0.5 x SSC and 0.1% SDS at room temperature. The filter was exposed with Kodak X-AR
film and an intensifying screen at -20°C for 3 d.
StatisticalAnalysis.
￿
Statistical analysis was performed by two-tailed Student's t-test. Data
are presented as mean t SEM.
Results
Effect ofCytokines on MonocyteHLA-DR Expression.
￿
Normal human peripheralblood
adherent cells(>90% nonspecific esterase-positive) were incubated either in the pres-
ence of medium or medium plus recombinant cytokine. After 48 h, HLA-DR ex-
pression was determined by FACS analysis. Table I summarizes the results ofthese
experiments. The concentration of each cytokine was chosen based on near-maximal
activity in standard biological assays (e.g., CTLL proliferation for IL-2). More ex-
tensive dose responses were performed with TNFot (1-500 ng/ml), CSF1 (10-1,000
U/ml), IL-4 (5-100 U/ml), and IFN-y (1-500 U/ml). The concentration with the
TABLE I
Effect of Cytokines on Monocyte HLA-DR Expression
Data presented as mean t SEM. p > 0.1 unless otherwise indicated.
' Relative MFC = MFC cytokine/MFC medium.
Cytokine n Concentration Relative MFC'
GM-CSF 16 800 U/ml 2.54 t 0.33 (p < 0.001)
IFN-.y 16 100 U/ml 5.14 t 0.60 (p < 0.001)
TNF-a 9 40 ng/ml 1 .31 t 0.06 (p < 0.02)
IL-4 4 50 U/ml 1 .20 f 0.03 (p < 0.01)
IL-10 3 40 U/ml 1 .05 t 0.04
IL-2 4 10 ng/ml 1 .01 t 0.06
IL-3 2 50 U/ml 0.97
IL-6 3 100 U/ml 1 .01 t 0.06
CSFA 5 1000 U/ml 1 .03 t 0.05868 CYTOKINE-MEDIATED INDUCTION OF HLA-DR, DQ ON MONOCYTES
maximal activity was used for these cytokines (see Table I). CSF1 (M-CSF), IL-1,
IL-2, IL-3, and IL-6 had no effect on HLA-DR expression. TNFtx increased sur-
face HLA-DR (p < 0.02), but the effect was small. Similarly, IL-4 induced a modest
increase in monocyte Ia expression (p < 0.01).
As expected, IFN-y was the most powerful inducer of HLA-DR, increasing ex-
pression to 5.14 t 0.60 ofcontrol monocytes (p < 0.001). The only other cytokine
that increased Iaat least twice control was GM-CSF(relative MFC = 2.54 t 0.33,
p<0.001). Fig. 1 shows representativehistogramsofGM-CSF and IFN-'v mediated
HLA-DRinduction. To rule outthepossibilitythat the effect ofGM-CSFwas modified
by contaminating LPS, similar experiments were performed in the presence and
absence ofpolymyxin B (16 jig/ml). No significant difference was observedbetween
the two conditions (data not shown).
UsingFAGS analysis, relative cellvolume wasestimatedusingforwardlightscatter
forGM-CSFtreated monocytesand control monocytesand therewas nosignificant
difference (data not shown). Therefore, the increase in MFC in GM-CSF cultures
wasdueto a change in antigendensityratherthan simply duetoanincreaseincell size.
Characterization ofSurfaceAntigenModulation by GM-CSF.
￿
Fig. 2 shows arepresen-
tative dose response fortheinductionofHLA-DRby GM-CSF An effect wasgenerally
observedwith 25 U/ml andwas maximal with 80-800 U/ml. Inkineticsexperiments,
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FIGURE 1.
￿
Representative histograms oftheeffect of GM-CSF and IFN-,y on HLA-DR,HLA-
DQ and Mo2 expression by monocytes. Vertical axis of each histogram represents relative cell
number and horizontal axis represents relative fluorescence. In the first column (i.e., cells cul-
tured in medium alone), the shaded histogram represents cells stained with the indicated mAb
and the open histogram showsthe cellsstained with the control antibody. In the GM-CSF and
IFN-.y columns, both the shaded histograms (cytokine-treated cells) and the open histograms
(cells cultured in medium)representcells stainedas indicatedon therighthand side ofthefigure.80
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an increase in DR expression was detected within 24 h and was usually maximum
after 48 h (data not shown).
GM-CSF also modulated the surface expression ofother monocyte antigens (Figs.
1 and 2). For instance, GM-CSF induced the expression of HLA-DQ on human
monocytes. The cytokine was also a potent downregulator of CD14 (a monocyte/
macrophage-specific surface protein detected by the mAb Mo2). Surface expression
of CD14 is also decreased by IFN-'Y (11).
HLA-DR Induction by GM-CSF Is Not Mediated by IFN-y.
￿
Because the effect of
GM-CSF on HLA-DR, HLA-DQ and Mo2 paralleled that of IFN-y, we consid-
ered whether the GM-CSF acted through the induction of IFN-y production by
contaminating T cells in vitro. This was felt to be unlikely because the cells studied
contained <1% CD3+ cells. Furthermore, IL-2, which is known to induce T cell
IFN-y production (14, 15), had no effect on Ia expression. Finally, further T cell
depletion by SRBC rosetting before plastic adherence did not interfere with GM-
CSFmediated HLA-DR induction (data not shown). To address this possibility di-
rectly, monocytes were incubated with GM-CSF in the presence of a neutralizing
mAb to IFN-y. The antibody alone had no effect on HLA-DR expression. Table
II shows that anti-IFN-gamma antibody neutralized 77% of IFN-ymediated HLA-
DR induction, but had no effect on GM-CSFmediated HLA-DR expression.
Interactions Between GM-CSFand Other Cytokines.
￿
The effect of GM-CSF on HLA-
DR expression was additive with low levels of IFN-,y (see Table III for a representa-
TABLE II
Effect of GM-CSF Is Not Mediated through IFN-,y
FIGURE 2. Dose responses of the
effect ofGM-CSF on the expression of
HLA-DR, HLA-DQ and Mo2 onhu-
man monocytes. Cellswere incubated
for 48 h inthe presenceofdifferent con-
centrations ofGM-CSF Results are ex-
pressed as absolute mean fluorescence
channel (MFC).
Samples were preincubated with or without anti-IFN-y antibody for 1 h before
addition to monocytes. Cells were harvested after 48 h. Standard error is <2
channel in each case.
' Data presented as MFC.
Alone Plus anti-IFN--y
Medium 18' 18
GM-CSF (800 U/ml) 31 31
IFN-,y (10 U/ml) 91 35870
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TABLE
III
Interaction
Between GM-CSF and IFN-y, TNF-a, and IL-4~`
"
Monocytes were cultivated for 2 d with either medium or the combination of
cytokines
indicated
.
Similar results were seen in two to four separate ex-
periments.
$
MFG, mean fluorescence channel in linear scale
.
Standard errorwas <2 chan-
nel
in each case
.
tive
experiment)
.
In the presence of high concentrations of IFN--y, however, GM-
CSF
had no additional effect
.
In contrast, TNFa, which slightly increased HLA-DR
expression
on normal human monocytes, synergized with GM-CSF in the induc-
tion
of DR
.
IL-4 had a slightly additive effect with GM-CSF (see Table III)
.
CSF1,
IL-1,
and IL-2 had no effect on GM-CSFmediated modulation of Ia antigens (data
not
shown)
.
GM-CSF
Increases HLA-DR mRNA Levels
.
￿
To
determine whether GM-CSF in-
creased
expression of class II MHC genes, cytoplasmic RNA was prepared from
adherent
monocytes and mRNA was analyzed by Northern blot analysis
.
HLA-DR
mRNA
levels from monocytes cultured either in medium or GM-CSF for 2 d was
determined.
HLA-DR mRNA content was higher in the GM-CSFtreated mono-
cytes
compared with control monocytes (see Fig
.
3)
.
The
HLA-DR-inducing Factor in Synovial Tissue (ST)Explant Supernatants is Neutralized
by
Anti-GM-CSFAntibody High levels of surface HLA-DR expression in the syno-
vial
lining is a cardinal finding in RA (1)
.
Culture supernatants from synovial tissue
cells
contain a factor that induces HLA-DR expression on normal monocytes and
is
not neutralized by anti-IFN-y antibody (3)
.
Because we have recently shown that
GM-CSF
is produced locally by the rheumatoid synovium and is present in RA
synovial
effusions (5), we tested the ability of a specific mAb to GM-CSF to neu-
tralize
the non-IFN-y Ia-inducing activity in joint samples
.
Culture supernatants
from
four rheumatoid synovial tissue explants were incubated with normal mono-
cytes
in the presence or absence of anti-GM-CSF antibody for 48 h
.
In each case,
GM-CSF
and IFN-y
MFC1
Medium 16
GM-CSF
(800 U/ml)
29
IFN-y
(1 U/ml)
25
GM-CSF
(800 U/ml) + IFN-
35
IFN-y
(100 U/ml)
65
GM-CSF
(800 U/ml) + IFN-y (100 U/ml)
64
GM-CSF
and TNF-a
Medium 15
GM-CSF
(800 U/ml)
36
TNF-a
(40 ng/ml)
17
GM-CSF
(800 U/ml) + TNF-a (40 ng/ml)
53
GM-CSF
and IL-4
Medium 26
GM-CSF
(800 U/ml)
43
IL-4
(50 U/ml)
35
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(800 U/ml) + IL-4 (50 U/ml)
48U
100
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FIGURE 3 .
￿
InductionofHLA-DR 0 chainmRNA byGM-
CSFandIFN-y . Monocyteswere cultured in medium, 800
U/ml GM-CSF, or 100U/ml IFN--y for2d . Approximately
20 lAg/ml ofcytoplasmicRNAwas loaded in each lane. Actin
and HLA-DR probes were simultaneously hybridized to
the nylon membrane. The density of the actin band was
proportional to the totalRNAcontent asjudgedby ethidium
bromide staining .
® No anti-OM-CSF
0 anti-OM-CSF
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FIGURE 4 . Effect of anti-GM-CSF
mAbon synovial tissue explant super-
natant-mediatedHLA-DR induction .
Samples were preincubated with anti-
GM-CSF antibody (350 U/ml ofneu-
tralizing activity) for 1 h at room tem-
perature before addition to cultures .
After 48 h, cells were harvested and
stained . Results are expressed as
AMFC (mean fluorescence channel of
test cells minus theMFCofcontrol cells
cultured in the presence of medium
alone) .
the antibody prevented induction of HLA-DR (see Fig . 4) (OMFCST = 39.5 t
5.7 ; OMFCST+anti-GM-CSF = 4.7 t 2.4 ; p < 0.01) . The antibody did not interfere
with UN-y-mediatedHLA-DR induction . Anti-IFN-y antibody didnot neutralize
the factor in synovial tissue supernatants (data not shown) .
Discussion
This study represents a comprehensive examination of the la-inducing capacity
of a number of cytokines on normal human monocytes . Ofparticular interest is the
observation that GM-CSF induced high levels of surface HLA-DR and HLA-DQ
expression . The observation that GM-CSF induces la expression on human cells
of monocyte/macrophage lineage has precedence in murine systems. For instance,
GM-CSF increases class II antigen expression on murine peritoneal macrophages
(6) . Also, GM-CSFderived bone marrow macrophages express more la than M-872 CYTOKINE-MEDIATED INDUCTION OF HLA-DR, DQ ON MONOCYTES
CSF derived cells in mice (7). However, there are no studies describing the effect
ofGM-CSF on Ia expression on human cells. In addition to its effect on Iadensity,
GM-CSF also downregulated CD14 on monocytes. Low CD14 expression, particu-
larly in association with high levels of surface HLA-DR, has been described as an
activation phenotype for human monocytes and macrophages (11). This phenotype
hasbeennoted in inflammatory synovial fluids (16), aswellas alveolar macrophages
from patients with sarcoidosis (17).
Quantitative variation in Iaexpression plays a major role in immune regulation
(18). The ability ofGM-CSF to modulate HLA-DR and DQmay have important
physiological implicationsin the normal immune response. Forexample, parenteral
administration ofGM-CSF to mice augments the primary antibody response (6).
This effect is due to enhanced function ofAPCs, including increased la expression
(6, 9). The fact that monocytes and macrophages obtained from inflammatory foci
resemble GM-CSFtreated monocytes suggests that local production of GM-CSF
(eitherwithor without IFN-y) could play arole inmacrophage activation in disease
states.
As a rule, cytokines are noted for highly redundant activities, but the ability to
induce HLA-DR expression was limited to only a few. GM-CSF and IFN-y were
by far the most powerful mediators. The increase in surface HLA-DR expression
after GM-CSF exposure corresponded to an increase in HLA-DR mRNA levels,
which suggests that the mechanism was pretranslational. TNFa, which reportedly
induces Iaonmurine macrophage celllines (19) and HLA-DR onsomehuman tumor
cells (20), had alimited (albeit statistically significant) activity. More striking, how-
ever, wasits abilityto synergizewith GM-CSF. Previous reportshave suggestedthat
IL-4 is an la inducer on human monocytes (21, 22) and murine macrophages (23,
24). Although our data confirm this, the degree ofactivity was much less than that
found for either IFN-y or GM-CSF CSF1 (M-CSF) has been reported to increase
Ia expression on human monocytes cultured in serum-free medium(25). However,
in our system, none of the other factors tested (CSF1, IL-1, IL-2, IL-3, IL-6)
significantly altered monocyte Ia expression either alone or in combination with
GM-CSF.
One ofthe most consistent findings in the synovium ofpatients with RA is the
large amount oflaantigens detected on the macrophage-like type A synovial lining
cells and synovial tissue macrophages (1). Because these cells are derived from the
bone marrow (9) and are likely either related to or derived from monocytes in the
peripheral blood, monocytes are a convenient model for studying synovial macro-
phage HLA-DR expression. The precise site where cells receive the signal is not
known, although it is often presumed to be intra-articular. The identification ofIa-
inducing factors in the joint would support this. In previous investigations of the
mechanism oflainduction on macrophagesinthejoint we have demonstrated that:
(a)lowlevels ofIFN-y are present inthejointinRA (3); (b) monocytes frompatients
with RA are not uniquely sensitive to the effects oflow levels ofIFN-y (4); and (c)
a non IFN-y Ia-inducing factor is present in rheumatoid synovial fluid and culture
supernatants ofRA synovial cells (3). Two lines ofevidence support the notion that
GM-CSF is an Ia-inducingfactor in RA. First, usingbioassays and a specific RIA,
significant levels ofGM-CSF have been identified in RAjoint samples (5). Hence,
this protein is present in sufficient quantities in thejoint (40-140 U/ml in synovial
tissue supernatants) to account for the activated phenotypes (i.e., high la and lowALVARO-GRACIA ET AL.
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CD14) (16) observed. Second, the Ia-inducingactivity in RA synovial tissue super-
natants was blocked by antibody to GM-CSF, but not by antibody to IFN-,y.
Although GM-CSF is likely an important Ia-inducing factor in the joint, other
cytokines are probably also involved. For instance, low levels of IFN-,y (similar to
those found in synovial fluid) have an additive effect on GM-CSFmediated induc-
tion of HLA-DR expression. TNFa, which has also been reported in RA synovial
fluid (26), synergizes with GM-CSF Therefore, the induction and maintenance of
the large amounts of class II molecules on the surface of rheumatoid macrophages
andsynoviocytes is likely dueto complex interactions of GM-CSF, TNFa, lowlevels
of IFN-,y and possibly other cytokines. Studies to identify the cells responsible for
secretion of these cytokines are currently in progress.
Summary
Granulocyte/macrophage CSF (GM-CSF) has recently been identified in rheu-
matoid arthritis (RA) synovial effusions. To studya potential role for GM-CSF and
othercytokineson theinductionof HLA-DR expression on monocytes andsynovial
macrophages, we analyzed the relative ability of recombinant human cytokines to
induce the surface expression ofclass II MHC antigens on normal peripheral blood
monocytes by FACS analysis. GM-CSF (800 U/ml) (mean fluorescence channel 2.54
t 0.33 times the control, p< 0.001) and IFN-,y (100 U/ml) (5.14 t 0.60, p< 0.001)
were the most potent inducers of HLA-DR. TNFa and IL-4 also increased HLA-
DR expression, although to a lesser degree (1.31 t 0.06 (p < 0.02) and 1.20 t 0.03
(p < 0.01), respectively]. IL-1 (40 U/ml), IL-2 (10 ng/ml), IL-3 (50 U/ml), IL-6 (100
U/ml), and CSF1 (1,000 U/ml) did not affect surface HLA-DR density. GM-CSF
also increased HLA-DR mRNA expression and surface HLA-DQ expression, but
decreased CD14 (a monocyte/macrophage antigen) expression. The effect of GM-
CSF on HLA-DR was not mediated by the generation of IFN-y in vitro because
it was not blocked by anti-IFN-y mAb. GM-CSF was additive with IL-4 and low
amounts (<3 U/ml) of IFN-,y and synergistic with TNFa. Because we have recently
reported that supernatants ofcultured RA synovial cells produceanon-IFN-yfactor
that induces HLA-DR on monocytes, we then attempted to neutralize this factor
with specific anti-GM-CSF mAb. Four separate synovial tissue supernatants were
studied, andthe antibody neutralized the HLA-DRinducing factor in each (p <0.01).
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